
Europe Stem Cell Assay Market Report and Forecast 2024-2032
Description
Europe Stem Cell Assay Market Report and Forecast 2024-2032
Europe Stem Cell Assay Market Report and Forecast 2024-2032
Europe Stem Cell Assay Market Outlook
The global stem cell assay market size was valued at USD 6.4 billion in 2023, with Europe holding a significant market share. The market is driven by the rising technological innovations in the field of stem cell assays. It is expected to grow at a CAGR of 20.10% during the forecast period of 2024-2032, with the values likely to attain USD 19.4 billion by 2032.
Key Takeaways
- On January 1, 2023, it was estimated that more than one-fifth of the population of the European Union was aged 65 years and above. The rising aging population fuels the need for novel therapeutic solutions, which directly impacts the market demand.
- One of the major Europe stem cell assay market trends is the rising technological advancements in the field of stem cell assays such as automation and high-throughput screening technologies which are likely to boost efficiency and improve the accuracy of stem cell research and testing.
- The rising impetus for stem cell research coupled with the presence of a robust research infrastructure in the region is likely to elevate market value. For instance, in June 2023, the University of Cambridge initiated a stem cell-based human embryo model project in the United Kingdom.
Stem cell assays are laboratory tests that are used to evaluate the behavior or function of stem cells. In Europe, they are widely utilized in clinical and research settings to obtain data on stem cell differentiation, viability, and proliferation, among others. These assays are increasingly employed in cancer research and regenerative medicine to find potential treatments for various diseases. The rising prevalence of chronic conditions including diabetes, cardiovascular diseases, and neurodegenerative disorders is expected to drive the Europe stem cell assay market growth in the coming years.
The market is significantly impacted by the rising aging population. On January 1, 2023, it was estimated that more than one-fifth of the population of the European Union was aged 65 years and above, with the median age reaching 44.5 yea rs. This growing size of the aging population in Europe reflects the need for novel therapeutic solutions, including those developed through stem cell research, which is likely to drive the market demand in the forecast period.
The rising integration of advanced and automated cell counting methods to assess stem cell viability is leading to a reduction in analyst-dependent variability and the analytical time in research labs and manufacturing facilities . This is anticipated to propel the Europe stem cell assay market demand. Additionally, these rising technological advancements in the field of stem cell assays such as high-throughput screening technologies are likely to boost efficiency and improve the accuracy of stem cell research and testing, thereby supporting market growth.
In Europe, the rising emphasis for stem cell research coupled with the presence of an established research infrastructure in the region is accelerating market growth. For instance, in June 2023, the University of Cambridge launched a project involving stem cell-based human embryo models in the United Kingdom. Such stem cell-based research activities are likely to augment the demand for various types of stem cell assays to understand stem cell biology and consequently develop stem cell therapies, ultimately elevating the market value.
Europe Stem Cell Assay Market Segmentation
Market Breakup by Cell Type
- Adult Stem Cells
- Human Embryonic Stem Cells
- Pluripotent
- Viability/Cytotoxicity Assays
- Isolation and Purification Assays
- Cell Identification Assays
- Proliferation Assays
- Differentiation Assays
- Function Assays
- Apoptosis Assays
- Others
- Flow Cytometers
- Cell Imaging and Analysis Systems
- Microelectrode Arrays
- Automated Cell Counters
- Kits
- Allogeneic Stem Cell Therapy
- Autologous Stem Cell Therapy
- Syngeneic Stem Cell Therapy
- Regenerative Medicine and Therapy Development
- Drug Discovery and Development
- Clinical Research
- Others
- Biopharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Others
- United Kingdom
- Germany
- France
- Italy
- Others
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Thermo Fisher Scientific
- PerkinElmer
- Stemcell Technologies
- Merck
- Bio-Rad Laboratories
- Agilent Technologies
- Promega
- Bio-Techne
- Cell Biolabs
FAQs
- What is the Europe stem cell assay market forecast outlook for 2024-2032?
- What are the major factors aiding the Europe stem cell assay market demand?
- What are the major Europe stem cell assay market trends?
- What is the market segmentation based on the cell type?
- What is the market breakup by type?
- What is the market segmentation based on product and services?
- What are the various treatments available in the market?
- What are the applications of stem cell assay?
- What are the major end users of stem cell assay?
- What is the market segmentation by countries?
- Who are the key players involved in the Europe stem cell assay market?
Meta description
Europe stem cell assay market is poised for growth, driven by the expansion of the global market, which was valued at USD 6.4 billion in 2023 and is projected to grow at a CAGR of 13.18% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Europe Stem Cell Assay Market Overview
- 3.1 Europe Stem Cell Assay Market Historical Value (2017-2023)
- 3.2 Europe Stem Cell Assay Market Forecast Value (2024-2032)
- 4 Europe Stem Cell Assay Market Landscape*
- 4.1 Europe Stem Cell Assay: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Europe Stem Cell Assay: Product Landscape
- 4.2.1 Analysis by Product
- 4.2.2 Analysis by Cell Type
- 4.2.3 Analysis by Treatment
- 5 Europe Stem Cell Assay Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Analysis
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Europe Stem Cell Assay Market Segmentation (2017-2032)
- 6.1 Europe Stem Cell Assay Market (2017-2032) by Cell Type
- 6.1.1 Market Overview
- 6.1.2 Adult Stem Cells
- 6.1.3 Human Embryonic Stem Cells
- 6.1.4 Pluripotent
- 6.2 Europe Stem Cell Assay Market (2017-2032) by Type
- 6.2.1 Market Overview
- 6.2.2 Viability /Cytotoxicity Assays
- 6.2.3 Isolation & Purification Assays
- 6.2.4 Cell Identification Assays
- 6.2.5 Proliferation Assays
- 6.2.6 Differentiation Assays
- 6.2.7 Function Assays
- 6.2.8 Apoptosis Assays
- 6.2.9 Others
- 6.3 Europe Stem Cell Assay Market (2017-2032) by Product & Service
- 6.3.1 Market Overview
- 6.3.2 Flow Cytometers
- 6.3.3 Cell Imaging & Analysis Systems
- 6.3.4 Microelectrode Arrays
- 6.3.5 Automated Cell Counters
- 6.3.6 Kits
- 6.4 Europe Stem Cell Assay Market (2017-2032) by Treatment
- 6.4.1 Market Overview
- 6.4.2 Allogeneic Stem Cell Therapy
- 6.4.3 Autologic Stem Cell Therapy
- 6.4.4 Syngeneic Stem Cell Therapy
- 6.5 Europe Stem Cell Assay Market (2017-2032) by Application
- 6.5.1 Market Overview
- 6.5.2 Regenerative Medicine &Therapy Development
- 6.5.3 Drug Discovery & Development
- 6.5.4 Clinical Research
- 6.5.5 Others
- 6.6 Europe Stem Cell Assay Market (2017-2032) by End User
- 6.6.1 Market Overview
- 6.6.2 Biopharmaceutical & Biotechnology Companies
- 6.6.3 Academic & Research Institutes
- 6.6.4 Others
- 6.7 Europe Stem Cell Assay Market (2017-2032) by Countries
- 6.7.1 Market Overview
- 6.7.2 United Kingdom
- 6.7.3 Germany
- 6.7.4 France
- 6.7.5 Italy
- 6.7.6 Others
- 7 United Kingdom of Stem Cell Assay Market (2017-2032)
- 7.1 United Kingdom Stem Cell Assay Market (2017-2032) by Cell Type
- 7.1.1 Market Overview
- 7.1.2 Adult Stem Cells
- 7.1.3 Human Embryonic Stem Cells
- 7.1.4 Pluripotent
- 7.2 United Kingdom Stem Cell Assay Market (2017-2032) by Type
- 7.2.1 Market Overview
- 7.2.2 Viability /Cytotoxicity Assays
- 7.2.3 Isolation & Purification Assays
- 7.2.4 Cell Identification Assays
- 7.2.5 Proliferation Assays
- 7.2.6 Differentiation Assays
- 7.2.7 Function Assays
- 7.2.8 Apoptosis Assays
- 7.2.9 Others
- 7.3 United Kingdom Stem Cell Assay Market (2017-2032) by Product & Service
- 7.3.1 Market Overview
- 7.3.2 Flow Cytometers
- 7.3.3 Cell Imaging & Analysis Systems
- 7.3.4 Microelectrode Arrays
- 7.3.5 Automated Cell Counters
- 7.3.6 Kits
- 7.4 United Kingdom Stem Cell Assay Market (2017-2032) by Treatment
- 7.4.1 Market Overview
- 7.4.2 Allogeneic Stem Cell Therapy
- 7.4.3 Autologic Stem Cell Therapy
- 7.4.4 Syngeneic Stem Cell Therapy
- 7.5 United Kingdom America Stem Cell Assay Market (2017-2032) by End User
- 7.5.1 Market Overview
- 7.5.2 Biopharmaceutical & Biotechnology Companies
- 7.5.3 Academic & Research Institutes
- 7.5.4 Others
- 7.6 United Kingdom Stem Cell Assay Market (2017-2032) by Application
- 7.6.1 Market Overview
- 7.6.2 Regenerative Medicine &Therapy Development
- 7.6.3 Drug Discovery & Development
- 7.6.4 Clinical Research
- 7.6.5 Others
- 8 Germany Stem Cell Assay Market (2017-2032)
- 8.1 Germany Stem Cell Assay Market (2017-2032) by Cell Type
- 8.1.1 Market Overview
- 8.1.2 Adult Stem Cells
- 8.1.3 Human Embryonic Stem Cells
- 8.1.4 Pluripotent
- 8.2 Germany Stem Cell Assay Market (2017-2032) by Type
- 8.2.1 Market Overview
- 8.2.2 Viability /Cytotoxicity Assays
- 8.2.3 Isolation & Purification Assays
- 8.2.4 Cell Identification Assays
- 8.2.5 Proliferation Assays
- 8.2.6 Differentiation Assays
- 8.2.7 Function Assays
- 8.2.8 Apoptosis Assays
- 8.2.9 Others
- 8.3 Germany Stem Cell Assay Market (2017-2032) by Product & Service
- 8.3.1 Market Overview
- 8.3.2 Flow Cytometers
- 8.3.3 Cell Imaging & Analysis Systems
- 8.3.4 Microelectrode Arrays
- 8.3.5 Automated Cell Counters
- 8.3.6 Kits
- 8.4 Germany Stem Cell Assay Market (2017-2032) by Treatment
- 8.4.1 Market Overview
- 8.4.2 Allogeneic Stem Cell Therapy
- 8.4.3 Autologic Stem Cell Therapy
- 8.4.4 Syngeneic Stem Cell Therapy
- 8.5 Germany Stem Cell Assay Market (2017-2032) by End User
- 8.5.1 Market Overview
- 8.5.2 Biopharmaceutical & Biotechnology Companies
- 8.5.3 Academic & Research Institutes
- 8.5.4 Others
- 8.6 Germany Stem Cell Assay Market (2017-2032) by Application
- 8.6.1 Market Overview
- 8.6.2 Regenerative Medicine &Therapy Development
- 8.6.3 Drug Discovery & Development
- 8.6.4 Clinical Research
- 9 France Stem Cell Assay Market (2017-2032)
- 9.1 France Stem Cell Assay Market (2017-2032) by Cell Type
- 9.1.1 Market Overview
- 9.1.2 Adult Stem Cells
- 9.1.3 Human Embryonic Stem Cells
- 9.1.4 Pluripotent
- 9.2 France Stem Cell Assay Market (2017-2032) by Type
- 9.2.1 Market Overview
- 9.2.2 Viability /Cytotoxicity Assays
- 9.2.3 Isolation & Purification Assays
- 9.2.4 Cell Identification Assays
- 9.2.5 Proliferation Assays
- 9.2.6 Differentiation Assays
- 9.2.7 Function Assays
- 9.2.8 Apoptosis Assays
- 9.2.9 Others
- 9.3 France Stem Cell Assay Market (2017-2032) by Product & Service
- 9.3.1 Market Overview
- 9.3.2 Flow Cytometers
- 9.3.3 Cell Imaging & Analysis Systems
- 9.3.4 Microelectrode Arrays
- 9.3.5 Automated Cell Counters
- 9.3.6 Kits
- 9.4 France Stem Cell Assay Market (2017-2032) by Treatment
- 9.4.1 Market Overview
- 9.4.2 Allogeneic Stem Cell Therapy
- 9.4.3 Autologic Stem Cell Therapy
- 9.4.4 Syngeneic Stem Cell Therapy
- 9.5 France Stem Cell Assay Market (2017-2032) by End User
- 9.5.1 Market Overview
- 9.5.2 Biopharmaceutical & Biotechnology Companies
- 9.5.3 Academic & Research Institutes
- 9.5.4 Others
- 9.6 France Stem Cell Assay Market (2017-2032) by Application
- 9.6.1 Market Overview
- 9.6.2 Regenerative Medicine &Therapy Development
- 9.6.3 Drug Discovery & Development
- 9.6.4 Clinical Research
- 9.6.5 Others
- 10 Italy Stem Cell Assay Market (2017-2032)
- 10.1 Italy Stem Cell Assay Market (2017-2032) by Cell Type
- 10.1.1 Market Overview
- 10.1.2 Adult Stem Cells
- 10.1.3 Human Embryonic Stem Cells
- 10.1.4 Pluripotent
- 10.2 Italy Stem Cell Assay Market (2017-2032) by Type
- 10.2.1 Market Overview
- 10.2.2 Viability /Cytotoxicity Assays
- 10.2.3 Isolation & Purification Assays
- 10.2.4 Cell Identification Assays
- 10.2.5 Proliferation Assays
- 10.2.6 Differentiation Assays
- 10.2.7 Function Assays
- 10.2.8 Apoptosis Assays
- 10.2.9 Others
- 10.3 Italy Stem Cell Assay Market (2017-2032) by Product & Service
- 10.3.1 Market Overview
- 10.3.2 Flow Cytometers
- 10.3.3 Cell Imaging & Analysis Systems
- 10.3.4 Microelectrode Arrays
- 10.3.5 Automated Cell Counters
- 10.3.6 Kits
- 10.4 Italy Stem Cell Assay Market (2017-2032) by Treatment
- 10.4.1 Market Overview
- 10.4.2 Allogeneic Stem Cell Therapy
- 10.4.3 Autologic Stem Cell Therapy
- 10.4.4 Syngeneic Stem Cell Therapy
- 10.5 Italy Stem Cell Assay Market (2017-2032) by End User
- 10.5.1 Market Overview
- 10.5.2 Biopharmaceutical & Biotechnology Companies
- 10.5.3 Academic & Research Institutes
- 10.5.4 Others
- 10.6 Italy Stem Cell Assay Market (2017-2032) by Application
- 10.6.1 Market Overview
- 10.6.2 Regenerative Medicine &Therapy Development
- 10.6.3 Drug Discovery & Development
- 10.6.4 Clinical Research
- 10.6.5 Others
- 11 Regulatory Framework
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Funding and Investment Analysis
- 13.1 Analysis by Funding Instances
- 13.2 Analysis by Type of Funding
- 13.3 Analysis by Funding Amount
- 13.4 Analysis by Leading Players
- 13.5 Analysis by Leading Investors
- 13.6 Analysis by Geography
- 14 Partnership and Collaborations Analysis
- 14.1 Analysis by Partnership Instances
- 14.2 Analysis by Type of Partnership
- 14.3 Analysis by Leading Players
- 14.4 Analysis by Geography
- 15 Supplier Landscape
- 15.1 Market Share by Top 5 Companies
- 15.2 Thermo Fisher Scientific
- 15.2.1 Financial Analysis
- 15.2.2 Product Portfolio
- 15.2.3 Demographic Reach and Achievements
- 15.2.4 Mergers and Acquisitions
- 15.2.5 Certifications
- 15.3 PerkinElmer
- 15.3.1 Financial Analysis
- 15.3.2 Product Portfolio
- 15.3.3 Demographic Reach and Achievements
- 15.3.4 Mergers and Acquisitions
- 15.3.5 Certifications
- 15.4 Stemcell Technologies
- 15.4.1 Financial Analysis
- 15.4.2 Product Portfolio
- 15.4.3 Demographic Reach and Achievements
- 15.4.4 Mergers and Acquisitions
- 15.4.5 Certifications
- 15.5 Merck
- 15.5.1 Financial Analysis
- 15.5.2 Product Portfolio
- 15.5.3 Demographic Reach and Achievements
- 15.5.4 Mergers and Acquisitions
- 15.5.5 Certifications
- 15.6 Bio-Rad Laboratories
- 15.6.1 Financial Analysis
- 15.6.2 Product Portfolio
- 15.6.3 Demographic Reach and Achievements
- 15.6.4 Mergers and Acquisitions
- 15.6.5 Certifications
- 15.7 Agilent Technologies
- 15.7.1 Financial Analysis
- 15.7.2 Product Portfolio
- 15.7.3 Demographic Reach and Achievements
- 15.7.4 Mergers and Acquisitions
- 15.7.5 Certifications
- 15.8 Promega
- 15.8.1 Financial Analysis
- 15.8.2 Product Portfolio
- 15.8.3 Demographic Reach and Achievements
- 15.8.4 Mergers and Acquisitions
- 15.8.5 Certifications
- 15.9 Bio-Techne
- 15.9.1 Financial Analysis
- 15.9.2 Product Portfolio
- 15.9.3 Demographic Reach and Achievements
- 15.9.4 Mergers and Acquisitions
- 15.9.5 Certifications
- 15.10 Cell Biolabs
- 15.10.1 Financial Analysis
- 15.10.2 Product Portfolio
- 15.10.3 Demographic Reach and Achievements
- 15.10.4 Mergers and Acquisitions
- 15.10.5 Certifications
- 16 Europe Stem Cell Assay Market – Distribution Model (Additional Insight)
- 16.1 Overview
- 16.2 Potential Distributors
- 16.3 Key Parameters for Distribution Partner Assessment
- 17 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 18 Company Competitiveness Analysis (Additional Insight)
- 18.1 Very Small Companies
- 18.2 Small Companies
- 18.3 Mid-Sized Companies
- 18.4 Large Companies
- 18.5 Very Large Companies
- 19 Payment Methods (Additional Insight)
- 19.1 Government Funded
- 19.2 Private Insurance
- 19.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.